Details for Patent: 6,090,395

Summary for Patent: 6,090,395

Title:	Stable hydroalcoholic compositions
Abstract:	A hydroalcoholic lotion is disclosed which comprises (a) a lower alcohol and water in a weight ratio of about 35:65 to 100:0, and (b) between at least 0.5% and 8% by weight thickener system comprised of at least one emulsifier present in at least 0.05% by weight wherein the composition in a polymer free state has a viscosity of at least 4,000 centipoise at 23 degrees C. and wherein the emulsifier is comprised of at least one hydrophobic group and at least one hydrophilic group. The hydroalcoholic composition is useful as a hand preparation such as a lotion or as a presurgical scrub replacement.
Inventor(s):	Robert A. Asmus, Matthew T. Scholz, Jill R. Charpentier
Assignee:	3M Innovative Properties Co
Application Number:	US08/781,565
Patent Claim Types: see list of patent claims	Composition; Use;

Analysis of United States Drug Patent 6,090,395: Scope, Claims, and Landscape

What is United States Patent 6,090,395?

United States Patent 6,090,395, titled "1-(4-substituted-phenyl)piperidines and their use as sigma 1 receptor ligands," was granted on July 18, 2000, to Solvay Pharmaceuticals, Inc. The patent claims a class of chemical compounds, specifically 1-(4-substituted-phenyl)piperidines, and their therapeutic application in treating conditions mediated by the sigma 1 receptor. These compounds have demonstrated affinity for sigma 1 receptors and are proposed for use in alleviating pain, neurodegenerative diseases, and psychiatric disorders.

The assignee, Solvay Pharmaceuticals, Inc., is now part of Abbott Laboratories following Abbott's acquisition of Solvay's pharmaceutical business in 2009. This patent is a foundational piece of intellectual property related to a specific chemical scaffold targeting the sigma 1 receptor.

What Does the Patent Claim?

Patent 6,090,395 protects a genus of chemical compounds defined by specific structural features and their pharmaceutical utility.

Chemical Compound Claims

The core claims of the patent define the chemical structures covered. The primary independent claim, Claim 1, outlines the general structure:

A compound of the formula:

Drugs Protected by US Patent 6,090,395

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,090,395

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	6103496
Australia	715468
Canada	2224702
Germany	69630221
European Patent Office	0833606
European Patent Office	1407761